BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Pain clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for pain: 393 (277 sponsors; 96 newly posted in the last 180 days, 16 stopped in the last 180 days; 63 new-entrant sponsors). Momentum score 18.4, rank 32 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 6, Phase 1 32, Phase 2 53, Phase 3 59, Phase 4 10, N/A 233.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Eli Lilly and Company LLY | 9 | P3 4, P2 5 | 2 | 3 |
| EMS | 4 | P3 4 | 0 | 1 |
| Vertex Pharmaceuticals Incorporated VERX | 4 | P3 3, P2 1 | 0 | 3 |
| Ambros Therapeutics, Inc. | 3 | P3 2, NA 1 | 2 | 0 |
| Novo Nordisk A/S NVO | 3 | P3 2, P1 1 | 1 | 1 |
| Pfizer PFE | 3 | P2 1, P3 2 | 2 | 1 |
| AFT Pharmaceuticals, Ltd. | 2 | P3 2 | 0 | 1 |
| Shanghai Huilun Pharmaceutical Co., Ltd. new entrant | 2 | P3 2 | 2 | 0 |
| Haisco Pharmaceutical Group Co., Ltd. | 3 | P3 1, P2 2 | 0 | 1 |
| AbbVie ABBV | 2 | NA 1, P3 1 | 0 | 1 |
| Adneuris Therapeutics, Inc. new entrant | 2 | P3 1, P2 1 | 2 | 2 |
| Amgen AMGN | 2 | P3 1, NA 1 | 0 | 0 |
| Gelscom SAS | 2 | P3 1, NA 1 | 0 | 0 |
| Genascence Corporation | 2 | P1 1, P3 1 | 1 | 0 |
| TLC Biopharmaceuticals, Inc. | 2 | P2 1, P3 1 | 0 | 0 |
| Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | 2 | P1 1, P3 1 | 1 | 0 |
| Ache Laboratorios Farmaceuticos S.A. new entrant | 1 | P3 1 | 1 | 1 |
| Aponia Laboratories, Inc. new entrant | 1 | P3 1 | 1 | 0 |
| Asklepion Pharmaceuticals, LLC | 1 | P3 1 | 0 | 0 |
| Avenue Therapeutics, Inc. ATXI | 1 | P3 1 | 0 | 0 |
| Brainfarma Industria Química e Farmacêutica S/A new entrant | 1 | P3 1 | 1 | 0 |
| Cali Pharmaceuticals LLC | 1 | P3 1 | 0 | 0 |
| Dexa Medica Group new entrant | 1 | P3 1 | 1 | 1 |
| DiscGenics, Inc. | 1 | P3 1 | 0 | 0 |
| Ensysce Biosciences ENSC | 1 | P3 1 | 0 | 0 |
New-entrant sponsors: Shanghai Huilun Pharmaceutical Co., Ltd., Adneuris Therapeutics, Inc., Ache Laboratorios Farmaceuticos S.A., Aponia Laboratories, Inc., Brainfarma Industria Química e Farmacêutica S/A, Dexa Medica Group.
Recently stopped trials
- NCT02711254 Moximed - terminated: Adequate data has been collected Phantom Knee System Clinical Trial
- NCT05732818 Spinal Stabilization Technologies - suspended: The study was suspended as enrollment of patients was difficult and no participants could be found for two years. Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy 3
- NCT06980948 Sangamo Therapeutics - suspended: Study is suspended while Sangamo seeks a new sponsor for the ST-503-101 study Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
- NCT07344090 Qwince Innovation S.r.l. - terminated: Failure to reach the target sample size Using a Decision-making System to Support the Management of Fever and Acute Pain in Children
- NCT04652687 VIVEX Biologics, Inc. - terminated: Sponsor decision. VIA Disc NP Registry
- NCT00426985 Alkemira SA - terminated: Sponsor (Endo Pharmaceuticals) decision (business reasons) Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Ten
- NCT07449325 VahatiCor, Inc. - suspended: Study suspended to implement a protocol change Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
- NCT07600203 Erchonia Corporation - withdrawn: Study terminated due to insufficient participant enrollment Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ
- NCT05104268 E2Bio Life Sciences, LLC - withdrawn: Unable to recruit due to the relatively infrequent occurrence of oral mucositis. No participants enrolled Study of a New Medical Device for Oral Mucositis
- NCT03953846 Phoenix Kinetics - terminated: Active Implants Europe closed operations NUsurface Implant Registry
- NCT03127592 Apsen Farmaceutica S.A. - terminated: recruitment difficulty Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Ver
- NCT00663468 Phoenix Kinetics - terminated: Lead surgeon retired. Treatment of Sub-capital Fractures of Hip Joint by Using TriboFit™ Acetabular Buffer
- NCT06128369 Oculis - terminated: Sponsor decision to close study due to third-party administrative error preventing analysis of trial results. There was no issue in terms of A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment
- NCT04860635 Arthritis Innovation Corporation - suspended: Study superseded by alternative Phase 3 trial Safety of F14 Following Total Knee Replacement
- NCT00766402 Johnson & Johnson Taiwan Ltd - terminated: An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With A
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-22 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07533786 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | Pain After Surgery | recruiting | 200 |
| 2026-11-30 est. | P3 | Saol Therapeutics Inc | NCT07226258 Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | active not recruiting | 150 |
| 2026-12 est. | P2 | 3D Medicines | NCT05265052 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain | Cancer Pain | not yet recruiting | 177 |
| 2026-12 est. | P2 | Dianthus Therapeutics DNTH | NCT06537999 A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy | active not recruiting | 46 |
| 2026-12 est. | P2 | Dogwood Therapeutics Inc. DWTX | NCT06848348 Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pa | active not recruiting | 240 |
| 2026-12 est. | P3 | Harrow Inc HROW | NCT07832552 A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surg | Postoperative Ocular Inflammation; Postoperative Ocular Pain | enrolling by invitation | 250 |
| 2026-12-15 est. | P2/P3 | Janssen Research & Development, LLC | NCT05327114 Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | recruiting | 201 |
| 2026-12-31 est. | P2/P3 | Olatec Therapeutics, Inc. | NCT05658575 Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Acute Gout Flare; Gout Attack; Gout Flare; Gouty Arthritis; Gout; Arthritis; Joint Pain | recruiting | 300 |
| 2027-01 est. | P3 | Adneuris Therapeutics, Inc. | NCT07845071 An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin | Pain | recruiting | 160 |
| 2027-01-20 est. | P1/P2 | Creative Medical Technology Holdings Inc CELZ | NCT06053242 Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | Chronic Low-back Pain; Degenerative Disc Disease | active not recruiting | 45 |
| 2027-01-25 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT06696443 Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathic Pain | active not recruiting | 455 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07551739 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Pain After Surgery | not yet recruiting | 200 |
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar Removal | Acute Pain; Molar; Molar, Third; Surgery, Oral | recruiting | 212 |
| 2026-11 est. | P1/P2 | Bexion Pharmaceuticals, Inc. | NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Metastatic Colorectal Carcinoma; Neuropathy | active not recruiting | 195 |
| 2026-10-04 | P2 | Bausch & Lomb Incorporated BLCO | NCT07412496 A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy | Pain, Postoperative | completed | 130 |
| 2026-10-01 | P2 | Nuvig Therapeutics, Inc. | NCT07027111 Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 14 |
| 2026-10 est. | P2/P3 | Shanghai Huilun Pharmaceutical Co., Ltd. | NCT07709598 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery | Postoperative Pain | recruiting | 330 |
| 2026-10 est. | P2/P3 | Shanghai Huilun Pharmaceutical Co., Ltd. | NCT07699601 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery | Postoperative Pain | recruiting | 330 |
| 2026-10 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07159243 Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | not yet recruiting | 180 |
| 2026-09-30 est. | P2 | Tarian Pharma | NCT07082764 Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy | Chemotherapy Induced Peripheral Neuropathy | not yet recruiting | 30 |
| 2026-09 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06994507 GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer | Chemotherapy-induced Peripheral Neuropathy (CIPN) | recruiting | 352 |
| 2026-09 est. | P3 | argenx ARGX | NCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | Multifocal Motor Neuropathy (MMN); MMN | active not recruiting | 154 |
| 2026-09 est. | P3 | Eidos Therapeutics, a BridgeBio company | NCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | withdrawn | |
| 2026-08 est. | P3 | Ensysce Biosciences ENSC | NCT06602271 PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | Postoperative Pain, Acute | recruiting | 320 |
| 2026-07-20 | P2 | Immunovant Sciences GmbH IMVT | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 94 |
| 2026-07-16 | P2 | Immunovant Sciences GmbH IMVT | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 26 |
| 2026-07 est. | P2 | TLC Biopharmaceuticals, Inc. | NCT06574269 A Study on TLC590 for Managing Postsurgical Pain | Postsurgical Pain Management | recruiting | 120 |
| 2026-06-26 | P2 | Novo Nordisk A/S NVO | NCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy | completed | 142 |
| 2026-06-17 | P2 | SoLa Pelvic Therapy | NCT06673108 Vaginal Photobiomodulation for Chronic Pelvic Pain | Chronic Pelvic Pain; Chronic Pelvic Pain Syndrome (CPPS) | completed | 128 |
| 2026-06-12 | P3 | TLC Biopharmaceuticals, Inc. | NCT07222748 A Study of TLC590 for Postsurgical Pain Following Bunionectomy | Postoperative Pain | active not recruiting | 304 |
| 2026-06-10 | P3 | Sanofi SNY | NCT06290128 A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do | Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinatin | active not recruiting | 109 |
| 2026-06 est. | P2 | Vaneltix Pharma, Inc. | NCT06394830 Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis; Bladder Pain Syndrome | recruiting | 50 |
| 2026-06 est. | P2 | Vaneltix Pharma, Inc. | NCT05737121 Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS | Interstitial Cystitis; Bladder Pain Syndrome | recruiting | 120 |
| 2026-06 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT01451853 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy | withdrawn | |
| 2026-05-26 | P2 | Syqe Medical | NCT06490445 A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) | Diabetic Peripheral Neuropathic Pain | completed | 122 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "pain"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.